Loading...
An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss
Rosiglitazone is an insulin-sensitizing thiazolidinedione (TZD) that activates the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Although rosiglitazone effectively treats type II diabetes mellitus (T2DM), it carries substantial complications, including increased frac...
Na minha lista:
| Udgivet i: | J Bone Miner Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4472363/ https://ncbi.nlm.nih.gov/pubmed/25257948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.2364 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|